UBS Group
SLXN

UBS Group’s Silexion Therapeutics SLXN Stock Holding History

UBS Group’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$662 Sell
52
-117
-69% -$2.05K ﹤0.01% 9795
2025
Q4 		$3.25K Buy
169
+100
+145% +$3.01K ﹤0.01% 9067
2025
Q3 		$2.35K Sell
69
-659
-91% -$54.7K ﹤0.01% 9184
2025
Q2 		$88.5K Buy
728
+242
+50% +$32.8K ﹤0.01% 7331
2025
Q1 		$80.2K Buy
486
+387
+391% +$76.6K ﹤0.01% 7216
2024
Q4 		$29.9K Buy
99
+88
+800% +$37.3K ﹤0.01% 7608
2024
Q3 		$7.91K Buy
+11
New +$17.3K ﹤0.01% 7869

Other funds holding SLXN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's SLXN Position: Q1 2026 in Review

UBS Group reduced its Silexion Therapeutics (SLXN) stake by 69% in Q1 2026, selling an estimated $2.05K and leaving 52 shares worth $662. The position accounts for ﹤0.01% of the portfolio, ranked #9795.

UBS Group first reported a position in SLXN in Q3 2024 and has held it in 7 quarters since. The position peaked at $88.5K in Q2 2025. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

  • UBS Group held 52 shares of Silexion Therapeutics worth $662 as of Q1 2026.
  • UBS Group sold 117 Silexion Therapeutics shares in Q1 2026, an estimated $2.05K.
  • Silexion Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9795 holding.
  • UBS Group first reported a position in Silexion Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • UBS Group's Silexion Therapeutics position peaked at $88.5K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.